Chardan Capital Reiterates “Buy” Rating for Coya Therapeutics (NASDAQ:COYA)

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating reissued by equities research analysts at Chardan Capital in a research note issued to investors on Thursday,Benzinga reports. They currently have a $14.00 price objective on the stock. Chardan Capital’s target price would indicate a potential upside of 173.44% from the stock’s previous close.

COYA has been the topic of several other reports. HC Wainwright reiterated a “buy” rating on shares of Coya Therapeutics in a research report on Monday, November 24th. Wall Street Zen raised Coya Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. BTIG Research lifted their target price on Coya Therapeutics from $15.00 to $16.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. D. Boral Capital reissued a “buy” rating and issued a $15.00 price target on shares of Coya Therapeutics in a report on Monday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Wednesday, October 8th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $16.00.

Coya Therapeutics Trading Down 0.6%

NASDAQ COYA traded down $0.03 during mid-day trading on Thursday, reaching $5.12. 382,054 shares of the company’s stock traded hands, compared to its average volume of 300,363. Coya Therapeutics has a 1-year low of $4.65 and a 1-year high of $8.29. The company has a fifty day simple moving average of $5.86 and a 200-day simple moving average of $6.05. The company has a market cap of $107.11 million, a price-to-earnings ratio of -4.61 and a beta of 0.25.

Coya Therapeutics (NASDAQ:COYA) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.12). Coya Therapeutics had a negative return on equity of 55.76% and a negative net margin of 462.24%.The company had revenue of $3.56 million for the quarter, compared to analyst estimates of $3.70 million. Equities research analysts forecast that Coya Therapeutics will post -1.15 earnings per share for the current fiscal year.

Institutional Trading of Coya Therapeutics

Institutional investors have recently made changes to their positions in the stock. Prosperity Wealth Management Inc. lifted its position in shares of Coya Therapeutics by 16.4% in the third quarter. Prosperity Wealth Management Inc. now owns 23,800 shares of the company’s stock worth $136,000 after buying an additional 3,350 shares during the last quarter. JPMorgan Chase & Co. acquired a new position in Coya Therapeutics during the third quarter valued at approximately $28,000. Lantern Wealth Advisors LLC bought a new position in shares of Coya Therapeutics in the third quarter valued at approximately $66,000. Jane Street Group LLC lifted its stake in shares of Coya Therapeutics by 101.7% in the first quarter. Jane Street Group LLC now owns 26,137 shares of the company’s stock worth $169,000 after buying an additional 13,176 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Coya Therapeutics in the second quarter worth $119,000. 39.75% of the stock is currently owned by institutional investors and hedge funds.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.